West Pharma’s New Org Chart: Visualizing the Lagarde Transition
A CEO transition at a $3 billion injectable-drug components manufacturer is a structural reset that arrives faster than most enterprise sellers can rebuild their account intelligence. West Pharmaceutical Services, which delivers over 41 billion components and devices annually, just replaced the executive who shaped its strategy for nearly a decade. The successor was hired specifically to accelerate high-margin contract manufacturing and GLP-1 delivery systems. For enterprise sales teams, this is not merely an executive change. It signals the beginning of a new operating phase. As demand for injectable therapies accelerates, particularly around GLP-1 treatments and advanced biologics, the internal priorities, budget flows, decision pathways, and stakeholder influence networks inside West are likely to evolve. Sellers relying on historical relationships or static account maps may soon discover that yesterday's buying committee no longer controls tomorrow's decisio...